BrainHealth

About BrainHealth

Jiangsu Hilexin Medical Technology Co., Ltd., also known as BrainHealth, is a medical device company established in December 2016 by founder and CEO Huang Yong. The company specializes in the development and industrialization of Tumor Treating Fields (TTF) technology, a physical therapy method for treating solid tumors. Hilexin is recognized as the first company in China and the second globally to successfully commercialize this technology and advance it to the registered clinical trial stage.

The firm's primary business involves the research, development, and production of Class III medical devices. Its core technology uses alternating electrical fields to specifically inhibit the division of cancer cells with minimal impact on healthy cells. Hilexin has developed a product pipeline targeting several difficult-to-treat cancers, including glioblastoma (GBM), pancreatic cancer, non-small cell lung cancer, and ovarian cancer. A key feature of its products is the proprietary flexible electrode technology, which is significantly thinner and lighter than traditional ceramic electrodes while offering superior functionality. The company has also been a pioneer in incorporating real-time temperature control into the TTF field.

Headquartered in Wuxi, Jiangsu, the company operates in the Chinese MedTech market, serving patients and collaborating with healthcare professionals. Hilexin has established strategic partnerships with major pharmaceutical companies like AstraZeneca and BeiGene to conduct a range of clinical trials. The business model focuses on making TTF therapy more accessible and affordable for patients in China. The company generates revenue through the sale of its medical devices and has attracted significant investment to fund its clinical trials and product development. It has completed multiple funding rounds, including a Series C round of 500 million RMB in May 2021, with investors such as Yunfeng Capital, Temasek, and Hillhouse Capital.